Quality Biological & JPT Announce Distribution and Marketing Agreement
News Sep 16, 2005
JPT Peptide Technologies GmbH and Quality Biological, Inc. (QBI) have announced the start of a non-exclusive distribution and marketing agreement for the USA.
Within the scope of this agreement, the parties join forces to better serve customers in the US.
This cooperation will enhance the numerous marketing activities underway and accelerate customer order processing with JPT.
"I am delighted that we could win Quality Biological as distributor for our peptide-based products and services in America,” stated Peter-Paul Henze, JPT's Director of Sales and Marketing, who heads the US office of JPT in Springfield, VA.
“They are part of the Mid-Atlantic scientific community; the scientists trust them and have relied on their products and support for decades.”
“QBI, in turn, knows us and has helped process our highly explanation-prone products for selected customers for some time now.”
“I am pleased that we can now offer the ease-of-mind they guarantee to all of our American customers."
"JPT brings a wealth of experience and some very cutting-edge technologies to the table," says Sol Graham, President and CEO, of Quality Biological, Inc.
"People think that peptides are a simple commodity, but our demanding clientele knows better and simply cannot afford to lose time or waste biological material, therefore we are pleased to partner with an innovative company which values its customers and provides quality products and services to the research community."
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.